Pfizer Begins Approval Process For Vaccinating Children Aged 5-11

After favourable results in an American Academy of Pediatrics (AAP) trial, Pfizer has now begun the process to get its vaccine approved for children aged 5-11. According to a spokeswoman, the trial results showed a favourable safety profile and a robust antibody response to two doses of the vaccine. The dose size for children aged 5-11 is around one-third of the standard dose size.

Pfizer has already started the application process for approval in Australia. So far, more than 53% of children aged 12-15 have received 1 jab of a vaccine despite the option only opening up 4 weeks ago. However, there will be considerable work needed before Pfizer can get the ‘green light’ for children 5-11 in Australia.